Gross Margin

A $170M deal to boost infant formula supply has soured for Perrigo, leading to a 25% stock crash, a strategic review, and securities fraud lawsuits.

A new memory module may seem obscure, but it’s a key piece of the puzzle for building trusted AI, resilient 5G, and reliable edge computing.

One company's move to standardize a traditional remedy highlights a key strategy for winning trust and market share in the booming wellness industry.

After a major turnaround, playable media firm Super League is betting its future on digital assets, bringing in heavyweights to lead its charge into Web3.

A new patent for reactivated carbon technology offers a circular solution to destroy "forever chemicals," promising a reliable path for U.S. water safety.

After a financial tightrope walk, Actelis Networks is back in Nasdaq's good graces. But the real story is its mission to secure our future's IoT.

Once mired in debt, Castellum has secured over $170M in prime contracts, signaling a dramatic resurgence in the competitive federal defense market.

The fashion giant beat earnings and initiated a dividend, but declining sales and consumer uncertainty reveal a complex picture for the apparel industry.

A new alliance explores how inanimate microbes, or postbiotics, could become a novel weapon in oncology, starting with breast cancer research.

NUS scientists unveil a microneedle patch for plants, slashing waste and boosting growth. A new investment frontier in high-end, sustainable agriculture.

A food-tech firm's pivot from quiet operator to public force reveals a savvy digital strategy, a key US acquisition, and a plan to dominate the 'better-for-you' market.

As the aging U.S. grid strains under explosive demand, industrial leaders are turning to microgrids for energy independence and financial stability.

Beyond the press release: Why Terreno's 107,000 sq. ft. deal with the Secret Service is a major indicator for the industrial real estate market.

A Swiss firm claims a CHF 480M raise and a $300M tech fund, but a closer look reveals a company with virtually no verifiable corporate footprint.

After two decades under its visionary founder, Oxford Nanopore taps a commercial scaling expert to lead its next chapter of global growth and market dominance.

New 48-month data for Xenon's azetukalner shows remarkable efficacy, but its real strategy to tackle the total burden of epilepsy may be the bigger story.